Pyridostigmine Bromide
FDA Approved, EMA Approved
Description
Pyridostigmine is a reversible cholinesterase inhibitor that increases acetylcholine availability at the neuromuscular junction. It is primarily used to treat myasthenia gravis but is also employed in managing ophthalmoplegia associated with neuromuscular disorders. The drug improves muscle strength and reduces fatigue in affected patients.
Indications & Therapeutic Use
myasthenia gravis, ophthalmoplegia, Lambert-Eaton syndrome
Linked Diseases:
ophthalmoplegia
H49.3D009886
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Pyridostigmine Bromide
| Generic Name | Pyridostigmine Bromide |
| Brands | 1 brand available |
| Active Ingredient | Pyridostigmine Bromide |
| Drug Class | myasthenia gravis |
| Manufacturer | Valeant Pharmaceuticals |
| Dosage Forms | Oral tablet, 60mg; Extended-release tablet, 180mg; Syrup, 60mg/5mL |
| Medical Code | N07AA02 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes